Cypher’s Speedy Sail To Reimbursement Not Typical, Veterans Caution

Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent's relatively easy path to reimbursement may have contributed to industry misconceptions about the coverage process, according to CR Bard's David Parr, VP-Reimbursement